Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s

Investing.com Gold reports: Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s. Full body text was unavailable at ingest time, so this brief is based on headline context.